Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.795 USD | +4.33% | +7.58% | +10.45% |
Financials (USD)
Sales 2024 * | 204K | Sales 2025 * | 11.85M | Capitalization | 196M |
---|---|---|---|---|---|
Net income 2024 * | -72M | Net income 2025 * | -62M | EV / Sales 2024 * | 964 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 16.6 x |
P/E ratio 2024 * |
-2.53
x | P/E ratio 2025 * |
-3.62
x | Employees | 24 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.15% |
Latest transcript on Outlook Therapeutics, Inc.
1 day | +3.14% | ||
1 week | +8.28% | ||
Current month | -26.63% | ||
1 month | -14.62% | ||
3 months | -1.88% | ||
6 months | -19.38% | ||
Current year | +11.17% |
Managers | Title | Age | Since |
---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 18-04-12 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 15-12-10 |
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +6.26% | - | |
0.00% | 147 M€ | +4.88% | - | |
0.00% | 18 M€ | +3.28% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 8.7 | +3.20% | 49 338 |
24-04-26 | 8.43 | +2.93% | 120,913 |
24-04-25 | 8.19 | -0.12% | 150,771 |
24-04-24 | 8.2 | 0.00% | 339,980 |
24-04-23 | 8.2 | +1.36% | 151,657 |
Delayed Quote Nasdaq, April 29, 2024 at 09:58 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.17% | 196M | |
+1.89% | 42.75B | |
+47.64% | 41.61B | |
+11.49% | 41.34B | |
-12.36% | 26.59B | |
+8.19% | 25.49B | |
-23.91% | 18.12B | |
+29.58% | 12.24B | |
-1.96% | 11.76B | |
+7.69% | 11B |
- Stock Market
- Equities
- OTLK Stock